SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

BRIGHT MINDS BIOSCIENCES INC.
Date: Aug. 27, 2025 · CIK: 0001827401 · Accession: 0000000000-25-009199

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-289581

Date
August 27, 2025
Author
Division of
Form
UPLOAD
Company
BRIGHT MINDS BIOSCIENCES INC.

Letter

Re: Bright Minds Biosciences Inc. Registration Statement on Form F-3 Filed August 26, 2025 File No. 333-289581 Dear Ian McDonald:

August 27, 2025

Ian McDonald Chief Executive Officer Bright Minds Biosciences Inc. 400 N Aberdeen St., Suite 900 Chicago, IL 60642

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jason Drory at 202-551-8342 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Michael Shannon

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 August 27, 2025

Ian McDonald
Chief Executive Officer
Bright Minds Biosciences Inc.
400 N Aberdeen St., Suite 900
Chicago, IL 60642

 Re: Bright Minds Biosciences Inc.
 Registration Statement on Form F-3
 Filed August 26, 2025
 File No. 333-289581
Dear Ian McDonald:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Jason Drory at 202-551-8342 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Michael Shannon
</TEXT>
</DOCUMENT>